Cleave Therapeutics Announces Acquisition of Clinical and Preclinical Assets
20 Jul 2023 //
BUSINESSWIRE
BioNTech inks cancer deal with Chinese biotech; Eikon, CASI buy Cleave’ assets
20 Jul 2023 //
ENDPTS
CASI AND CLEAVE THERAPEUTICS ANNOUNCE TRIAL APPLICATION APPROVAL FOR CB-5339
06 Jan 2023 //
PR NEWSWIRE
Cleave Licenses CB-5339 To CASI Pharmaceuticals For Greater China Region
08 Mar 2021 //
PRNEWSWIRE